Continental Grain-backed RNA material producer GreenLight Biosciences is hoping to supply ingredients for RNA-based coronavirus vaccines after securing $17m in funding.

GreenLight Biosciences, a US-based RNA production business backed by food and commodities group Continental Grain, has collected $17m in a round featuring Flu Lab, Xeraya Capital and Baird Capital. Founded in 2008, Greenlight has devised a bioprocessing method to facilitate large-scale production of ribonucleic acid – the biological molecule responsible for numerous genetic functions –…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.